LYRA — Lyra Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $310.07m
- $207.31m
- $1.56m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -16.3 | -22.1 | -43.5 | -55.3 | -62.7 |
Depreciation | |||||
Non-Cash Items | 0.411 | 1.77 | 2.77 | 6.27 | 3.98 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 2.11 | -0.879 | 13.9 | 4.55 | -4.88 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Cash from Operating Activities | -13.8 | -21.1 | -25.8 | -43.4 | -63.3 |
Capital Expenditures | -0.211 | -1.77 | -3.38 | -0.164 | -1.05 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | — | — | -64.8 | -11.5 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -0.211 | -1.77 | -3.38 | -65 | -12.6 |
Financing Cash Flow Items | -0.226 | -2.59 | -0.245 | -4.25 | -3.65 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -0.115 | 87.7 | 0.359 | 96.3 | 65.7 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -14.1 | 64.8 | -28.8 | -12.1 | -10.2 |